Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection.

Ilya TsimafeyeuRustem GafanovSvetlana ProtsenkoAnna SemenovaAni OganesyanNurzhan NurgaliyevSergei KrasnyAnastasia BondarenkoSufia SafinaKristina Zakurdaeva

Published in: Cancer immunology, immunotherapy : CII (2020)

The efficacy and safety profiles observed in this study support the administration of nivolumab in mRCC patients infected with HCV and warrant further investigation.

Keyphrases

end stage renal disease
hepatitis c virus infection
metastatic renal cell carcinoma
ejection fraction
newly diagnosed
chronic kidney disease
hepatitis c virus
peritoneal dialysis
human immunodeficiency virus
patient reported outcomes